Creating a new formulation to improve flu vaccines
DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151 for flu vaccines
['FUNDING_OTHER'] · MOLECULAR EXPRESS, INC. · NIH-10933265
This study is testing a new type of flu vaccine that uses special ingredients to boost your immune response, aiming to provide better protection against the flu, especially during flu season.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MOLECULAR EXPRESS, INC. (nih funded) |
| Locations | 1 site (RANCHO DOMINGUEZ, UNITED STATES) |
| Trial ID | NIH-10933265 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new formulation for flu vaccines that combines signal modifiers with a specific lipid to enhance the immune response. Using a proprietary liposomal system called VesiVax, the researchers aim to create a more effective vaccine that can better protect against the influenza virus. Patients may benefit from improved vaccine efficacy, leading to better protection during flu seasons. The research involves laboratory work primarily with animal models to test the new vaccine formulation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at higher risk for influenza, such as the elderly, young children, or those with compromised immune systems.
Not a fit: Patients who are not at risk for influenza or those who have already received a flu vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective flu vaccines that provide better protection against influenza.
How similar studies have performed: Other research has shown promise in enhancing vaccine efficacy through similar approaches, indicating potential for success in this area.
Where this research is happening
RANCHO DOMINGUEZ, UNITED STATES
- MOLECULAR EXPRESS, INC. — RANCHO DOMINGUEZ, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ONHO, SAM — MOLECULAR EXPRESS, INC.
- Study coordinator: ONHO, SAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.